Author

ME Gornet

Observed names: M. Gornet, M. K. Gornet, M.K. Gornet

Institutions: Johns Hopkins University, Johns Hopkins Medicine

Observed institutions: Mayo Clinic, Johns Hopkins University, Johns Hopkins Medicine, Mayo Clinic in Arizona, Mayo Clinic in Florida

OpenAlex ID: A5113037066

Chemotherapy for Advanced CNS Ependymoma

1999 · M.K. Gornet, J.C. Buckner, et al. · Journal of Neuro-Oncology · 63

Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma

2006 · R. D. Rao, H. E. Windschitl, et al. · Journal of Clinical Oncology · 35

Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma

2007 · D. G. Perez, V. Suman, et al. · Journal of Clinical Oncology · 13

N0377: Results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma

2007 · R. D. Rao, J. B. Allred, et al. · Journal of Clinical Oncology · 12

Surgical management vs primary radiotherapy for vulvar cancer

2017 · S.A. Sullivan, N. Desravines, et al. · Gynecologic Oncology · 2

Food and Drug Administration Database Secondary Analysis: Difference in Operative Hysteroscopy Device Safety Profiles

2024 · AN Valdez-Sinon, AM Madison, et al. · Journal of Minimally Invasive Gynecology

12471 AirSeal Insufflation Devices: A Review of Adverse Event Reports to the Food and Drug Administration

2024 · AN Valdez-Sinon, SL Olson, et al. · Journal of Minimally Invasive Gynecology

10570 The Robotic Tenaculum: A Review of Adverse Event Reports to the Food and Drug Administration

2023 · ME Gornet, A Frost, et al. · Journal of Minimally Invasive Gynecology

Contemporary recurrence and survival outcomes for stage IB squamous cell carcinoma of the vulva: Time to raise the bar

2017 · R.L. Stone, M. Gornet, et al. · Gynecologic Oncology

Works count: 9

Citation count: 125

H-index: 4

I10-index: 4